To this end, using PTEN-null prostate cancer cell lines, PC3 and C4-2, we established PTEN inducibly-overexpressing cell lines that targeted PTEN to the plasma membrane and nucleus, respectively. The gene discussed is PTEN; the disease is prostate cancer.